首页> 外文OA文献 >No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study

【2h】

No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study

机译：在Covid药物（Comet）研究中医院入院和临床进程之前，使用血管紧张素转化酶抑制剂或血管紧张素II受体阻滞剂之间的使用无关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Roos S. G. Sablerolles; Freija E. F. Hogenhuis; Melvin Lafeber; Bob P. A. Loo; Sander D. Borgsteede; Eric Boersma; Jorie Versmissen; Hugo Kuy;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study [J] . Sablerolles Roos S. G., Hogenhuis Freija E. F., Lafeber Melvin, British Journal of Clinical Pharmacology . 2021,第8期

机译：在Covid药物（Comet）研究中，使用血管紧张素转化酶抑制剂或血管紧张素II受体阻滞剂在医院 - 19的入院和临床过程中使用之间的关联
2. No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study [J] . Roos S. G. Sablerolles, Freija E. F. Hogenhuis, Melvin Lafeber, British journal of clinical pharmacology . 2021,第8期

机译：在Covid药物（Comet）研究中，使用血管紧张素转化酶抑制剂或血管紧张素II受体阻滞剂在医院 - 19的入院和临床过程中使用之间的关联
3. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial [J] . Lopes Renato D., Macedo Ariane V. S., de Barros E Silva Pedro G. M., JAMA: the Journal of the American Medical Association . 2021,第3期

机译：停止对Covid-19承认的患者在医院和医院中持续血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂的影响：随机临床试验
4. Ultrastructure and mechanical property of angiotensin II-stimulated tubular cells pretreated with angiotensin II type 1 receptor blocker [C] . Lee Gi-Ja, Ji-Hye Kim, Sung-Wook Kang, 2011 IEEE Nanotechnology Materials and Devices Conference . 2011

机译：血管紧张素II 1型受体阻滞剂预处理的血管紧张素II刺激的肾小管细胞的超微结构和力学性能
5. Comparison of monotherapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in improving health outcomes among veteran patients with type 2 diabetes. [D] . Campbell, Heather M. 2011

机译：与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂单一疗法改善2型糖尿病退伍军人患者健康结局的比较。
6. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome [O] . Katherine W Lam, Kenneth W Chow, Jonathan Vo, -1

机译：持续的医院内血管紧张素转化酶抑制剂和血管紧张素II受体阻滞剂在高血压Covid-19患者中使用与阳性临床结果有关
7. Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID ‐19, inflammation level, severity, and death in patients with COVID ‐19: A rapid systematic review and meta‐analysis [O] . Xiao Liu, Chuyan Long, Qinmei Xiong, 2020

机译：血管紧张素转化酶抑制剂和血管紧张素II受体阻滞剂具有Covid -19，炎症水平，严重程度和死亡患者的血管紧张素II受体阻滞剂-19 --19：快速系统审查和荟萃分析

No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study

著录项

相似文献

相关主题

期刊订阅